Erratum to: The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: An observational study in multiple institutes across Japan (JDDM27)(Diabetol Int, 10.1007/s13340-012-0073-z);The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: An observational study in multiple institutes across Japan (JDDM27)

Diabetology International

Volumn 3, Issue 3, 2012, Pages 164-173

  Kanatsuka, Azuma ^a   Kawai, Koichi ^b   Hirao, Koichi ^c   Yokoyama, Hiroki ^d   Kobayashi, Masashi ^e  

^a Chiba Central Medical Center   (Japan)

^b Kawai Clinic   (Japan)

^c HEC Science Clinic   (Japan)

^d Jiugaoka Medical Clinic Internal Medicine   (Japan)

^e Department of Neurosurgery   (Japan)

Author keywords

Insulin regimens; Observational study; Onset age; Oral anti diabetic drugs; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; GLYCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

EID: 84866744686     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-012-0085-8     Document Type: Erratum

References (33)

1. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44: 1249-58.
2. Levy J, Atkinson AB, Bell PM, McCance DR, Haddon DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998; 15: 290-6.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281: 2005-12.
4. Kahn SE, Haffner SM, Heise ME, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-43.
5. Hirssch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005; 23: 78-86.
6. Nahtan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29: 1963-72.
7. Kobayashi M, Yamazaki K, Hirao K, Japan Diabetes Clinical Data Management Study Group, et al. The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM1). Diab Res Clin Pract. 2006; 73: 198-204.
8. Holman RP, Kerensa I, Thorne MS, et al. Addition of biphasic or prandial insulin aspart reduced HbA1c levels more than the addition of basal insulin detemir. N Engl J Med. 2007; 357: 1716-30.
9. Concato J, Shah N, Holwitz RI. Randomized, controlled trials, observational studies, and the hierarch designs. N Engl J Med. 2000; 342: 1887-92.
10. MacKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Interpreting the evidence: choosing between randomized and non-randomized studies. BMJ. 1999; 319: 312-5.
11. ®-based analysis of clinical data obtained at multiple institutions (JDDM 3). Diab Res Clin Pract. 2006; 72: 277-83.
12. Yokoyama H, Kawai K, Oishi MJ, Sone H, on behalf of Japan Diabetes Data Management Study Group. Familial predisposition to cardiovascular risk and disease contributes to cardiovascular risk and disease interacting with other cardiovascular risk factors in diabetes-implication for common soil. Atherosclerosis. 2008; 201: 332-8.
13. Committee of Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee of Japan Diabetes Society on the Classification and Diagnosis of Diabetes Mellitus. J Japan Diab Soc 1999; 42: 395-404 (in Japanese).
14. Guideline Committee of the Japan Diabetes Society. Japan diabetes society guideline for the management of diabetes based on scientific evidences. Nankodo: Japan Diabetes Society; 2010 (in Japanese).
15. The Guideline for Epidemiology Study in Japan. The Ministry of Health, Labor and Welfare. June 30, 2003 (in Japanese).
16. Tominaga M, Makino E, Yoshino G, et al. Report of the committee on standardization of laboratory testing related to diabetes mellitus: The seventh national survey on Hemoglobin A1c. J Japan Diab Soc. 2003; 46: 961-5. (in Japanese).
17. American Diabetes Association. Clinical practice recommendations 1995. Diabetes Care. 1995; 18(suppl 1): S1-596.
18. UKPDS Group. UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med. 1994; 11: 534-44.
19. The Committee of the Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diab Invest 2010; 1: 212-28 (in Japanese).
20. Hayward AR, Maning WG, Kaplan SH, et al. Starting insulin therapy in type 2 diabetes. Effectiveness, complication, and resource utilization. JAMA. 1997; 278: 1663-9.
21. Cohen FJ, Conklin JE, Neslusan CA, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003; 26: 1847-51.
22. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen Mj. Analysis of observational studies in the presence of treatment selection bias: effect of invasive cardiac management on AMI survival using propensity score and instrumental variable. JAMA. 2007; 297: 278-85.
23. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tumori T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008; 359: 2220-32.
24. O'Rahily S, Barrosa I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning. Science. 2005; 307: 370-3.
25. Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, Uchigata Y, Omori Y. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997; 20: 844-7.
26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.
27. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of & 7% in type 2 diabetes. Meta-analysis of randomized controlled trials. Diabetes Care. 2011; 34: 510-7.
28. Lasserson DS, Glasziou P, Pererza R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2009; 52: 1990-2000.
29. Holman RR, Farmer AJ, Davis MJ, et al. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009; 361: 1736-47.
30. Rosennfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000; 37: 41-6.
31. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin dependent diabetes mellitus. Arch Intern Med. 1997; 157: 1249-55.
32. Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes. Arch Physiol Biochem. 2008; 114: 3-10.
33. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008; 118: 2992-3002.